Literature DB >> 20639486

CD30 ligand/CD30 plays a critical role in Th17 differentiation in mice.

Xun Sun1, Hisakata Yamada, Kensuke Shibata, Hiromi Muta, Kenzaburo Tani, Eckhard R Podack, Yasunobu Yoshikai.   

Abstract

A CD30 ligand (CD30L; CD153) and its receptor, CD30, is a membrane-associated glycoprotein belonging to the TNF superfamily and TNFR superfamily. These were expressed preferentially by activated CD4(+)T cells. In this paper, we show that CD44(low)CD62(hi)CD4(+) T cells from CD30L(-/-) or CD30(-/-) mice exhibited impaired differentiation into Th17 cells but an increased ability to produce IL-2 after in vitro culture under Th17-polarizing conditions. Neutralization with IL-2 by anti-IL-2 mAb partly restored the ability of Th17 differentiation in CD30L(-/-) or CD30(-/-) T cells. Stimulation via CD30L by immobilized anti-CD30L mAb suppressed IL-2 production by CD30(-/-)CD4(+) T cells, indicating that the reverse signal to CD30L is responsible for downregulation of IL-2 production. In vivo Th17 differentiation of CD30L(-/-)CD4(+)CD45RB(high) T cells was also impaired after transfer into SCID mice, whereas CD30L(+/+)CD4(+)CD45RB(high) T cells normally differentiated into Th17 cells in CD30L(-/-) SCID mice. The results of these studies demonstrate that CD30L/CD30 signaling executed by the T-T cell interaction plays a critical role in Th17 cell differentiation, at least partly via downregulation of IL-2 production.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20639486     DOI: 10.4049/jimmunol.1000024

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

Review 1.  Searching for "signal 2": costimulation requirements of γδ T cells.

Authors:  Julie C Ribot; Ana debarros; Bruno Silva-Santos
Journal:  Cell Mol Life Sci       Date:  2011-05-04       Impact factor: 9.261

2.  Targeted deletion of Traf2 allows immunosuppression-free islet allograft survival in mice.

Authors:  Jeanette E Villanueva; Stacey N Walters; Mitsuru Saito; Elisabeth K Malle; Nathan W Zammit; Katherine A Watson; Robert Brink; Nicole L La Gruta; Stephen I Alexander; Shane T Grey
Journal:  Diabetologia       Date:  2017-01-06       Impact factor: 10.122

3.  Optimal identification of human conventional and nonconventional (CRTH2-IL7Rα-) ILC2s using additional surface markers.

Authors:  Sucai Liu; Kapil Sirohi; Mukesh Verma; Jerome McKay; Lidia Michalec; Anand Sripada; Tomas Danhorn; Donald Rollins; James Good; Magdalena M Gorska; Richard J Martin; Rafeul Alam
Journal:  J Allergy Clin Immunol       Date:  2020-02-04       Impact factor: 10.793

Review 4.  Roles for TNF-receptor associated factor 3 (TRAF3) in lymphocyte functions.

Authors:  Zuoan Yi; Wai Wai Lin; Laura L Stunz; Gail A Bishop
Journal:  Cytokine Growth Factor Rev       Date:  2013-12-25       Impact factor: 7.638

Review 5.  CD30: from basic research to cancer therapy.

Authors:  Hiromi Muta; Eckhard R Podack
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

6.  CD30 is required for activation of a unique subset of interleukin-17A-producing γδ T cells in innate immunity against Mycobacterium bovis Bacillus Calmette-Guerin infection.

Authors:  Ying Guo; Xun Sun; Kensuke Shibata; Hisakata Yamada; Hiromi Muta; Eckhard R Podack; Yasunobu Yoshikai
Journal:  Infect Immun       Date:  2013-08-05       Impact factor: 3.441

7.  CD30-targeted therapy induces apoptosis of inflammatory cytokine-stimulated synovial fibroblasts and ameliorates collagen antibody-induced arthritis in mice.

Authors:  Minami Matsuhashi; Keiichiro Nishida; Misa Sakamoto; Yuka Gion; Aki Yoshida; Takayuki Katsuyama; Ryuichi Nakahara; Yoshihisa Nasu; Yoshinori Matsumoto; Yasuharu Sato; Toshifumi Ozaki
Journal:  Inflamm Res       Date:  2022-01-22       Impact factor: 4.575

Review 8.  Targeting costimulatory molecules to improve antitumor immunity.

Authors:  Daria Capece; Daniela Verzella; Mariafausta Fischietti; Francesca Zazzeroni; Edoardo Alesse
Journal:  J Biomed Biotechnol       Date:  2012-02-12

9.  Characterization of CD30/CD30L(+) Cells in Peripheral Blood and Synovial Fluid of Patients with Rheumatoid Arthritis.

Authors:  Alessandro Barbieri; Marzia Dolcino; Elisa Tinazzi; Antonella Rigo; Giuseppe Argentino; Giuseppe Patuzzo; Andrea Ottria; Ruggero Beri; Antonio Puccetti; Claudio Lunardi
Journal:  J Immunol Res       Date:  2015-05-19       Impact factor: 4.818

10.  Evaluation of serum levels of sCD30L ligand in patients with ovarian cancer in terms of selected clinico-pathological factors.

Authors:  Anita Chudecka-Głaz; Izabella Rzepka-Górska
Journal:  Contemp Oncol (Pozn)       Date:  2013-01-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.